Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

被引：19

作者：

Ogihara, Toshio ^{[1
]}

Saruta, Takao ^{[2
]}

Rakugi, Hiromi ^{[1
]}

Shimamoto, Kazuaki ^{[3
]}

Ito, Sadayoshi ^{[4
]}

Matsuoka, Hiroaki ^{[5
]}

Horiuchi, Masatsugu ^{[6
]}

Imaizumi, Tsutomu ^{[7
]}

Takishita, Shuichi ^{[8
]}

Higaki, Jitsuo ^{[6
]}

Katayama, Shigehiro ^{[9
]}

Saito, Ikuo ^{[2
]}

Shimada, Kazuyuki ^{[10
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka 5650871, Japan

[2] Keio Univ, Osaka, Japan

[3] Sapporo Med Univ, Sch Med, Osaka, Japan

[4] Tohoku Univ, Sch Med, Sendai, Japan

[5] Dokkyo Med Univ, Osaka, Japan

[6] Ehime Univ, Grad Sch Med, Osaka, Japan

[7] Kurume Univ, Sch Med, Osaka, Japan

[8] Univ Ryukyus, Sch Med, Osaka, Japan

[9] Saitama Med Univ, Osaka, Japan

[10] Jichi Med Univ, Osaka, Japan

来源：

HYPERTENSION RESEARCH | 2009年 / 32卷 / 02期

关键词：

clinical trial; combination therapy; olmesartan; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; TRIAL; AMLODIPINE; MEDOXOMIL; EFFICACY; OUTCOMES;

D O I：

10.1038/hr.2008.31

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being < 140 mm Hg for systolic BP and < 90 mm Hg for diastolic BR Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.

引用

页码：163 / 167

页数：5

共 24 条

[1] *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2] Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals
Brunner, Hans R.
Arakawa, Kikuo
[J]. CLINICAL DRUG INVESTIGATION, 2006, 26 (04) : 185 - 193
[3] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian, AV
Bakris, GL
Black, HR
Cushman, WC
Green, LA
Izzo, JL
Jones, DW
Materson, BJ
Oparil, S
Wright, JT
Roccella, EJ
[J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
[4] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
Dahlöf, B
Sever, PS
Poulter, NR
Wedel, H
Beevers, DG
Caulfield, M
Collins, R
Kjeldsen, SE
Kristinsson, A
McInnes, GT
Mehlsen, J
Nieminen, M
O'Brien, E
Östergren, J
[J]. LANCET, 2005, 366 (9489) : 895 - 906
[5] Composite outcomes in randomized trials - Greater precision but with greater uncertainty?
Freemantle, N
Calvert, M
Wood, J
Eastaugh, J
Griffin, C
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19): : 2554 - 2559
[6] Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502
[7] Rationale and design of the avoiding cardiovascular events through combination therapy in patients LIving with Systolic hypertension (ACCOMPLISH) trial -: The first Randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension
Jamerson, KA
Bakris, GL
Wun, CC
Dahlöf, B
Lefkowitz, M
Manfreda, S
Velazquez, EJ
Weber, MA
[J]. AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) : 793 - 801
[8] Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson, Kenneth
Weber, Michael A.
Bakris, George L.
Dahlof, Bjorn
Pitt, Bertram
Shi, Victor
Hester, Allen
Gupte, Jitendra
Gatlin, Marjorie
Velazquez, Eric J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) : 2417 - 2428
[9] *JAP SOC HYP, 2006, HYPERTENS RES, V39, pS1
[10] Hypertension management in diabetic patients: prescribing trends from 1999 to 2005 in three Japanese university hospitals
Kamijima, Yukari
Ooba, Nobuhiro
Yagame, Mitsunori
Samizo, Kazuo
Shimodozono, Yoshihiro
Kageyama, Shigeru
Horiguchi, Shingo
Nagai, Ryozo
Kusunoki, Tadashi
Kubota, Kiyoshi
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (09) : 904 - 911

← 1 2 3 →